4D Molecular Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2026 Annual Meeting of Stockholders held by 4D Molecular Therapeutics, Inc. on June 17, 2026. The meeting was conducted virtually via the internet. As of the record date on April 20, 2026, there were 52,274,735 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
A total of 44,038,022 shares were voted on three proposals:
- Proposal 1 (Election of Directors): Stockholders elected three Class III director nominees to serve until the 2029 Annual Meeting.
- Nancy Miller-Rich: 35,880,028 votes FOR.
- John F. Milligan, Ph.D.: 35,778,121 votes FOR.
- Shawn Cline Tomasello, MBA: 30,508,706 votes FOR (notably received 6,564,524 withheld votes).
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- 43,900,362 votes FOR.
- 55,763 votes AGAINST.
- 81,897 votes ABSTAIN.
- Proposal 3 (Executive Compensation): Stockholders approved, on an advisory non-binding basis, the named executive officers' compensation.
- 36,065,437 votes FOR.
- 940,414 votes AGAINST.
- 67,379 votes ABSTAIN.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of the Annual Meeting outcomes.
Key Facts for Investor Verification
- Verify the significant number of withheld votes (6,564,524) for director nominee Shawn Cline Tomasello, MBA, compared to the other nominees.
- Confirm the total number of broker non-votes (6,964,792) which were recorded for all three proposals.
- Review the Definitive Proxy Statement on Schedule 14A filed on April 28, 2026, for detailed background on the director nominees and executive compensation.
- Note that the independent auditor, PricewaterhouseCoopers LLP, was ratified for the fiscal year ending December 31, 2026.